SCHEMBL12216931

SCHEMBL12216931

CCCOC(COC)CN(C)C

nearest known ligand 0.33

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
LPAR6 P43657 2/20 0.33
LPAR1 Q92633 2/20 0.33
LPAR4 Q99677 2/20 0.33
LPAR5 Q9H1C0 2/20 0.33
LPAR2 Q9HBW0 2/20 0.33
LPAR3 Q9UBY5 2/20 0.33
PIK3CD O00329 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19325502 0.84 THRB (0.32) PIK3CD
SCHEMBL23171105 0.81 LPAR1 (0.42) LPAR6LPAR1LPAR4LPAR5LPAR2
SCHEMBL13132312 0.77 PIK3CD (0.34) PIK3CD
SCHEMBL12212556 0.77 PIK3CD (0.34) PIK3CD
SCHEMBL12083595 0.77 PIK3CD (0.34) PIK3CD
SCHEMBL15800638 0.77 LPAR6 (0.36) LPAR6LPAR1LPAR4LPAR5LPAR2
SCHEMBL12216943 0.76 LPAR1 (0.36) LPAR6LPAR1LPAR4LPAR5LPAR2
SCHEMBL17213403 0.75 CNR1 (0.40) LPAR6LPAR1LPAR4LPAR5LPAR2
SCHEMBL12418703 0.75 LPAR1 (0.42) LPAR6LPAR1LPAR4LPAR5LPAR2
SCHEMBL12734070 0.74 LPAR1 (0.50) LPAR6LPAR1LPAR4LPAR5LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10653780-B2 Amino lipids and methods for the delivery of nucleic acids THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2020-05-19 US disclosed
EP-3225621-A1 IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS Arbutus Biopharma Corporation (CA) 2017-10-04 EP disclosed
US-20160095924-A1 AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2016-04-07 US disclosed
US-20160095924-A1 AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2016-04-07 US disclosed
US-9139554-B2 Amino lipids and methods for the delivery of nucleic acids TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2015-09-22 US disclosed
US-9139554-B2 Amino lipids and methods for the delivery of nucleic acids TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2015-09-22 US disclosed
EP-2350043-B9 IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS TEKMIRA PHARMACEUTICALS CORP (CA) 2014-08-20 EP disclosed
EP-2350043-B1 IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS TEKMIRA PHARMACEUTICALS CORP (CA) 2014-03-26 EP disclosed
US-20110256175-A1 AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-10-20 US disclosed
US-20110256175-A1 AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-10-20 US disclosed
WO-2010042877-A1 IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160095924-A1 AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS NSUN3, SARNP, LDLR LPAR6 92/4885LPAR1 80/4885LPAR4 158/4885
US-10653780-B2 Amino lipids and methods for the delivery of nucleic acids NSUN3, SARNP, LDLR LPAR6 92/4885LPAR1 80/4885LPAR4 158/4885
US-20110256175-A1 AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS NSUN3, SARNP, LDLR LPAR6 92/4885LPAR1 80/4885LPAR4 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.